NEW YORK, Aug 29 – Oxagen of Abingdon, UK, and Cerylid Biosciences of Melbourne, said Wednesday that they had agreed to collaborate to jointly study the genetic basis of endometriosis.
Oxagen and Cerylid are planning to look for genes and SNPs that lead to endometriosis and to eventually find targets that will lead to new diagnostics and treatments for the disease, which is estimated to affect as many as 10 percent of women of reproductive age, the companies said.
Financial terms of the deal were not disclosed.
Oxagen and Cerylid are already working with academic groups to conduct separate family-based studies of endometriosis.
Oxagen is working with the Nuffield Department of Obstetrics & Gynecology at the University of Oxford, while Cerylid is conducting its program with the Gene CRC, a collaborative venture between Australian geneticists.
Oxagen’s other genetic programs are in cardiovascular disease, inflammatory disease, and metabolic and endocrine disorders. Cerylid is a pharmacogenomics company that combines gene discovery programs with its natural products library of 575,000 extracts.